Results 61 to 70 of about 103,335,528 (240)

Biophysical approaches for studying viral entry

open access: yesFEBS Letters, EarlyView.
Viruses infect all living organisms and have been responsible for major epidemics and pandemics. Their ongoing evolutionary battle with host defenses creates a constant need for improved tools to study viral behavior. Advancing methods to probe viral attachment, fusion, and genome release deepen our understanding of how infections begin and support the
Inbar Yosibash, Raya Sorkin
wiley   +1 more source

Aptamer‐based strategies against SARS‐CoV‐2 viruses

open access: yesBMEMat, 2023
The COVID‐19 pandemic, caused by SARS‐CoV‐2, has seriously threatened human life and security in recent years and has had a serious impact on economic development. A range of strategies, including antibodies, small‐molecule agents and vaccines, have been
Yihao Huang   +7 more
doaj   +1 more source

Neutralization titers of SARS-CoV-2-nLuc and SARS-CoV-2 variants of concern with sera of macaques prime-boost vaccinated with rVSV-msp-SARS-CoV-2-Gtc.

open access: yes, 2021
Three macaques were prime-immunized intramuscularly with 109 PFU rVSVInd-SARS-CoV-2-msp-SF-Gtc and boost-immunized with 109 PFU of rVSVInd-SARS-CoV-2-msp-SF-Gtc 20 days after the prime-immunization.
Taewoo Kim (1456888)   +30 more
core   +1 more source

Immune Responses in SARS-CoV-2, SARS-CoV, and MERS-CoV Infections: A Comparative Review [PDF]

open access: yes, 2022
Coronavirus, discovered in the 1960s, is able to infect human hosts and causes mild to serious respiratory problems. In the last two decades, the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-
Irani, Soussan, Soussan Irani
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Molecular Crowding Modulates SARS‐CoV‐2 Aptamer Affinity

open access: yesSmall Structures, 2023
SARS‐CoV‐2 aptamer is a favorable candidate for the recognition and detection of SARS‐CoV‐2, owing to its small size and easy synthesis. However, the issue of compromised binding affinities in real samples and targeting mutant SARS‐CoV‐2 hinder wide ...
Ting Song   +6 more
doaj   +1 more source

Genomic Sequencing and Phylogenomics of Cowpox Virus

open access: yesViruses, 2022
Cowpox virus (CPXV; genus Orthopoxvirus; family Poxviridae) is the causative agent of cowpox, a self-limiting zoonotic infection. CPXV is endemic in Eurasia, and human CPXV infections are associated with exposure to infected animals. In the Fennoscandian
Diana Diaz-Cánova   +5 more
doaj   +1 more source

Individuals identified as positive for anti-SARS-CoV-2 antibodies in the population without registered SARS-CoV-2 infections.

open access: yes, 2022
Individuals identified as positive for anti-SARS-CoV-2 antibodies in the population without registered SARS-CoV-2 infections.
Krystyna Dąbrowska (315930)   +13 more
core   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

open access: yesFEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Home - About - Disclaimer - Privacy